Outset Medical (NASDAQ:OM) Rating Increased to Hold at Wall Street Zen

Outset Medical (NASDAQ:OM) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

OM has been the topic of a number of other reports. Royal Bank Of Canada reissued a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a report on Wednesday, December 17th. Stifel Nicolaus reduced their price objective on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Finally, BTIG Research reaffirmed a “buy” rating and set a $17.00 target price on shares of Outset Medical in a research note on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Outset Medical Price Performance

NASDAQ:OM opened at $5.01 on Friday. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69. The business’s 50-day simple moving average is $4.40 and its two-hundred day simple moving average is $10.37. The stock has a market cap of $90.95 million, a PE ratio of -0.38 and a beta of 2.07. Outset Medical has a 52 week low of $3.10 and a 52 week high of $21.98.

Insiders Place Their Bets

In other Outset Medical news, EVP Marc Nash sold 5,375 shares of Outset Medical stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $27,520.00. Following the completion of the transaction, the executive vice president owned 42,785 shares in the company, valued at approximately $219,059.20. This trade represents a 11.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, General Counsel John L. Brottem sold 9,314 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $47,687.68. Following the completion of the transaction, the general counsel directly owned 36,957 shares of the company’s stock, valued at approximately $189,219.84. This trade represents a 20.13% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 35,989 shares of company stock valued at $180,073. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Outset Medical

Several institutional investors and hedge funds have recently modified their holdings of OM. Assenagon Asset Management S.A. boosted its position in Outset Medical by 34.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock worth $1,886,000 after purchasing an additional 131,381 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Outset Medical by 1,276.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 116,306 shares of the company’s stock worth $1,642,000 after acquiring an additional 107,854 shares in the last quarter. Alyeska Investment Group L.P. raised its position in Outset Medical by 10.2% during the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after acquiring an additional 150,000 shares during the period. Millennium Management LLC lifted its holdings in Outset Medical by 165.8% during the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after purchasing an additional 262,874 shares in the last quarter. Finally, Citadel Advisors LLC grew its position in shares of Outset Medical by 372.8% in the third quarter. Citadel Advisors LLC now owns 96,084 shares of the company’s stock valued at $1,357,000 after purchasing an additional 75,762 shares during the period.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.